

## RESEARCH ARTICLE

# Magnitude and associated factors of mortality among patients admitted with COVID-19 in Addis Ababa, Ethiopia

Genanew Kassie Getahun<sup>1\*</sup>, Amare Dinku<sup>2</sup>, Dube Jara<sup>3</sup>, Tewodros Shitemaw<sup>1</sup>, Zelalem Negash<sup>4</sup>

**1** Menelik II Medical and Health Science College, Kotebe Metropolitan University, Addis Ababa, Ethiopia,

**2** Yanet Health College, Addis Ababa, Ethiopia, **3** Debre Markos University, Debre Markos, Ethiopia,

**4** Yekatiit 12 Medical College, Addis Ababa, Ethiopia

\* [genanaw21kassaye@gmail.com](mailto:genanaw21kassaye@gmail.com)



## OPEN ACCESS

**Citation:** Getahun GK, Dinku A, Jara D, Shitemaw T, Negash Z (2023) Magnitude and associated factors of mortality among patients admitted with COVID-19 in Addis Ababa, Ethiopia. *PLOS Glob Public Health* 3(8): e0000420. <https://doi.org/10.1371/journal.pgph.0000420>

**Editor:** Flavio Finger, Epicentre MSF, SWITZERLAND

**Received:** March 5, 2022

**Accepted:** July 19, 2023

**Published:** August 17, 2023

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pgph.0000420>

**Copyright:** © 2023 Getahun et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** The authors received no specific funding for this work.

## Abstract

The COVID-19 pandemic continues to grow around the world and has caused enormous mortality and morbidity. The severity and mortality of coronavirus disease are associated with various comorbidities. The infection fatality rate was reported to be inconsistent with different studies. Therefore, the aim of this study was to assess the magnitude and factors associated with mortality among patients admitted to Eka Kotebe General Hospital, Addis Ababa, Ethiopia. An institutional-based cross-sectional study was conducted at Eka Kotebe General Hospital among patients who were admitted for COVID-19 from January 15, 2021, to June 30, 2021. A total of 393 records of patients were selected by simple random sampling. Data was extracted from compiled data forms where available information was already tabulated. Data was entered and analyzed using SPSS version 25. The determinant factors associated with mortality among COVID-19 patients were identified using bivariate and multivariable logistic regression analysis. A statistical association was declared with multivariable logistic regression using a 95% confidence interval and a P-value of less than 0.05. The proportion of COVID-19 mortality among patients admitted to Eka Kotebe General Hospital was 8.1% (95% CI (5.4–10.8%)). Age >50 years [AOR = 7.91; 95% CI (2.34–25.70)], being male [AOR = 2.09; 95% CI (1.20–3.65)], having diabetes mellitus [AOR = 2.64; 95% CI (1.30–5.35)], having hypertension [AOR = 2.67; 95% CI (1.22–5.88)] and having chronic kidney disease [AOR = 12.04; 95% CI (4.03–14.22)] were determinant factors of COVID-19 mortality. The current study findings revealed that COVID-19 mortality was high among hospitalized COVID-19 patients. Furthermore, age, gender, diabetes mellitus, hypertension, and chronic kidney disease were discovered to be independent predictors of COVID-19 mortality. Therefore, older COVID-19 patients and those with established comorbidities such as hypertension, diabetes, and end-stage renal disease should receive comprehensive preventative efforts, including vaccination.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

There has been a significant loss of human life as a result of the novel coronavirus illness 2019 (COVID-19), which is still spreading throughout the world and causing tremendous mortality and morbidity [1]. This has created an unmatched challenge for the provision of public health services [2]. Those who have had preexisting medical illnesses in the past or who are currently suffering from medical disorders are seriously affected [3].

African countries (with a median age of less than 20 years) have registered a lower number of severe COVID-19 cases and deaths than Europe and the United States (median age > 38 years), despite a number of underlying factors like malnutrition, risky livelihoods, cultural factors, economic factors, and overcrowding within urban settlements [4, 5]. A lower case fatality rate was also observed in Africa when compared to the Americas and Europe; however, it was more or less comparable to Asia [6].

Excess mortality measures have been used to assess the impact of COVID-19 pandemics on public health, particularly when there are concerns about the under-counting of deaths that are directly related to a particular event or cause [7]. The disruption of societal and health systems, deaths from other causes, and the long-term health impact of COVID-19 in Sub-Saharan Africa are uncertain, especially given the region's poor testing capacity [8, 9].

Ethiopia's Federal Ministry of Health reported the first COVID-19 case in Addis Ababa on March 13, 2020, and Ethiopia is one of the most severely affected African countries, suffering terrible economic and medical hardships [10]. A report by February 2022 indicates that Ethiopia is seeing a modest decline in COVID-19 infections. On average, 121 new illnesses were recorded each day, that is much lower than the highest daily average ever recorded since the outbreak started. Since the start of the pandemic, there have been 468,345 illnesses and 7,438 deaths attributed to the coronavirus throughout the nation [11].

It is well established that a number of comorbidities are connected to both the severity and mortality of coronavirus disease [12]. Findings from a prospective cohort study showed that hypertension (23.5%), obesity (19.6%), and osteoarthritis (14.9%) were the most common, whereas chronic viral hepatitis type C (0.6%), type B (0.3%), and HIV (0.3%) were the least common [13]. Moreover, patients with a history of cardiovascular illness, chronic lung disease, or diabetes had the worst prognosis and were more likely to experience deteriorating outcomes like acute respiratory distress syndrome (ARDS) and pneumonia [13, 14]. It was associated with a substantial risk of mortality and severe morbidity in cancer patients [15]. When comparing patients with COVID-19 who had been hospitalized without comorbidity, the risk of mortality was lower in COVID-19 patients admitted with diabetes mellitus, hypertension, or cardiovascular disease (CVD) [16].

COVID-19 is currently a global discussion topic in the media and with the public. The outbreak has been declared an emergency, with the community facing an increased risk of infection. To our knowledge, few studies have been undertaken in Africa at a time when the pandemic appears to be different from that of other continents in terms of virus dissemination speed and death toll. As a result, the purpose of this research was to look at the magnitude of mortality and its associated factors among COVID-19 patients admitted to the Eka Kotebe General Hospital treatment center, Addis Ababa, Ethiopia.

## Methods

### Time and place of study

The study was conducted in Addis Ababa, Ethiopia. Addis Ababa city has 11 sub-cities. The city administration had an estimated total population of 5,005,524, where 7.16% were children

under the age of five [17]. Eka Kotebe General Hospital (treatment center) is one of the seven federal government hospitals located in Addis Ababa. The hospital serves as a COVID-19 referral treatment center with more than 600 beds for COVID-19 patients and over 400 clinical staff. The hospital underwent extensive renovations and was converted into a COVID-19 treatment facility in September of 2019 where COVID-19 patients were isolated and treated as a result of the COVID-19 outbreak. The study was conducted between January 15, 2021, and June 30, 2021.

### Study design and population

An institutional-based cross-sectional study was conducted with randomly selected patients infected and confirmed by PCR tests of COVID-19 and admitted to Eka Kotebe General Hospital between January 15 and June 30, 2021. The total number of patients admitted with COVID-19 during the study period was 4,876.

### Inclusion and exclusion criteria

**Inclusion.** Patients who had been infected with COVID-19 and were admitted either to emergency, ICU, or critical care wards and who were more than 18 years old were included.

**Exclusion.** Patients who had incomplete documentation were excluded.

### Sample size and sampling procedure

The sample size was calculated using a single population proportion formula, considering the prevalence of COVID-19 mortality to be 50% to have the largest sample size with a 95% confidence level and a 5% margin of error. Finally, adding a non-response rate of 10%, it was 422.

With a simple random sampling technique, respondents were selected using the total number of admitted patients as a source population and their medical record numbers as a sampling frame. Subsequently, lottery methods were applied to select study participants randomly. In general, using the patient registry as a source document, random patients were selected in Eka Kotebe general hospital and admitted as COVID-19 patients.

### Study variables

**Dependent variables.** COVID-19 related mortality (yes or no) between January 15, to June 30, 2021.

**Independent variables.** Sociodemographic factors

Clinical factors

Comorbidities

Pregnancy and childbearing

Malnutrition and micronutrient deficiency

**Data collection procedures and quality control.** Data was gathered from hospital documents using checklists in various wards, such as the ICU, critical care units, and emergency rooms. Computer-based registration formats were used to collect the data. To ensure the quality of the data, two professional nurses were recruited, and training was given on the data collection procedures, purposes of the study, categorization, and coding of the data. Every day, the activities were reviewed and checked for completeness and relevance by the principal investigators. Finally, the collected data was transferred to a secured area.

## Operational definition

**Co-morbid disease.** A chronic disease or group of chronic diseases that are present concurrently in COVID-19-infected patients.

**Clients or patients.** COVID-19-hospitalized individuals or COVID-19-infected individuals admitted to Eka Kotebe General Hospital for medical treatment.

**Mortality.** The number of deaths out of all admitted individuals infected by COVID-19 in Eka Kotebe General Hospital.

**Data processing and analysis.** Data entry was made using Epi Data version 3.1 and exported to SPSS version 25, for further analysis. Frequencies, proportions, and summary statistics were used to describe the study population in relation to relevant variables. Basic assumptions for binary logistic regression were done and model fitness has been checked before running multiple logistic regression analysis. Initially, binary logistic regression analysis was employed to analyze the relationship between independent variables and COVID-19 related mortality, along with the odds ratio and its 95% confidence interval. The variables with a p-value less than 0.25 were then incorporated into a multivariable logistic regression model, as suggested by Hosmer and Lemeshow [18]. In addition, each morbidity was assessed at binary logistic regression for being a candidate of multivariable logistic regression analysis and for being an independent driver of COVID-19 related mortality in the final model. Variables with a p-value of less than 0.05 were used to declare their statistical significance. The result was finally presented using text, tables, and charts based on the characteristics of the data.

## Ethical consideration

Ethical approval was obtained from Yanet College's research and ethics board. A permission letter was secured from the institutional review board of Eka Kotebe General Hospital. Data was collected after receiving informed written consent from each study participant. Confidentiality was ensured by concealing the patient profile's name and any specific characteristics in favor of a code and medical registration number.

## Results

### Demographic characteristics of respondents


Out of a total of 422 patients and their respective records, 393 patients and records with complete responses were chosen, yielding a response rate of 93.1%. Of the total participants, 233 (59.3%) were under the age of 50. In terms of gender, nearly two-thirds of the 252 (64.1%) participants were males, with a male-to-female ratio of more than 3:2.

In addition, 141, or 35.9%, of the male participants in this study were under the age of 50, while the remaining 111, or 28.2%, were 50 or older. In contrast, 49 (12.5%) and 92 (23.4%) of the study's female participants were, respectively, under 50 and over 50.

### The magnitude of COVID-19 mortality

Of the total COVID-19 patients and records evaluated, 32 (8.1%; 95% CI: (5.4–10.8%)) died as a result of COVID-19-related illnesses (Fig 1).

Furthermore, a majority of the study participants (275, or 70%) had a co-morbidity, with hypertension and other cardiovascular disorders being the most prevalent (103, or 26.2%), whereas cancer and malnutrition-related comorbidities were the least common, at 12 (3.1%) and 9, (2.3%), respectively. Records of patients were also examined in order to categorize them based on the sorts of co-morbidities they had at the time of diagnosis (Table 1).



**Fig 1. COVID-19 mortality among patients admitted to the COVID treatment center in Eka Kotebe General Hospital, Addis Ababa, Ethiopia, 2021 (n = 393).**

<https://doi.org/10.1371/journal.pgph.0000420.g001>

### Factors associated with COVID-19 mortality

A binary logistic regression analysis was conducted to identify the presence of the association between COVID-19 mortality and different independent variables. In the bivariate logistic regression analysis, variables that scored a p-value of less than 0.25 were selected as candidate variables for the multivariable logistic regression analysis; accordingly, age, sex, COVID-19 associated with HIV/AIDS, DM, HTN, CHD, CKD, malnutrition, micronutrient deficiency, and GIT-related disease were found to be associated with COVID-19 mortality.

**Table 1. Medical conditions associated with COVID-19 among patients admitted to the COVID treatment center at Eka Kotebe General Hospital, Addis Ababa, Ethiopia, 2021 (n = 393).**

Characteristics	Frequency	Percentage
<b>Admission diagnosis</b>		
Tuberculosis	63	16.0
HIV/AIDS	47	12.0
Cancer (All types)	12	3.1
Hypertension	103	26.2
Diabetes mellitus	82	20.9
Chronic heart disease	31	7.9
Chronic liver disease	13	3.3
Chronic kidney disease	70	17.8
Pregnancy and child birth	25	6.4
Malnutrition	9	2.3
GIT related disease	67	17.0
Skin and musculoskeletal disorder	40	10.2
Psychiatry & nervous system disorder	45	11.5
Others	22	5.6
<b>COVID-19 associated with another comorbidity</b>		
Yes	275	70
No	118	30

<https://doi.org/10.1371/journal.pgph.0000420.t001>

**Table 2. Risk factors for death in COVID-19 patients admitted to Eka Kotebe Hospital in Addis Ababa, Ethiopia, in 2021 (n = 393).**

Variables	Death		COR (95% CI)	AOR (95%CI)
	Yes	No		
<b>Age of patients:</b>				
<50 years	8	245	1	1
≥50 years	24	116	6.34(2.76–14.53)	7.91(2.43–25.70) **
<b>Sex</b>				
Male	24	228	1.75(0.76–4.01)	2.09(1.20–3.65) *
Female	8	133	1	1
<b>HIV/AIDS and other hematologic disorders</b>				
Yes	13	34	6.58(2.99–14.48)	1.58(0.78–3.22)
No	19	327	1	1
<b>DM &amp; other metabolic disease</b>				
Yes	15	67	3.87(1.84–8.14)	2.64(1.30–5.35) **
No	17	294	1	1
<b>HTN &amp; vascular disease</b>				
Yes	16	87	3.15(1.51–6.56)	2.67(1.22–5.88) **
No	16	294	1	1
<b>CHD &amp; related disease</b>				
Yes	7	24	3.93(1.54–10.01)	2.69(0.98–4.93)
No	25	337	1	1
<b>CKD &amp; related disease</b>				
Yes	20	50	10.37(4.77–22.51)	12.04 (4.03–14.22)**
No	12	311	1	1
<b>Malnutrition and micro- nutrient deficiency</b>				
Yes	2	7	3.37(0.67–16.95)	2.04(0.83–4.02)
No	30	354	1	1
<b>Musculoskeletal and skin related disorders</b>				
Yes	7	34	2.22(0.85–5.77)	2.04(0.33–4.02)
No	25	327	1	1

\*Indicates a p-value < 0.05, and

\*\* shows a p-value < 0.01

<https://doi.org/10.1371/journal.pgph.0000420.t002>

Finally, the selected variables were entered into a multivariable logistic regression analysis. As a result, respondents aged 50 and above [AOR = 7.91, 95% CI: 2.34–25.69]; being male [AOR = 2.09, 95% CI: 1.20–3.65]; having diabetes mellitus [AOR = 2.67, 95% CI: 1.22–5.88]; and having chronic kidney disease [AOR = 12.04, 95% CI: 4.03–14.22] had a statistically significant association with COVID-19 mortality (Table 2).

## Discussion

The current study revealed that COVID-19 mortality was found to be 8.1% (95% CI: 5.4–10.8%) among patients admitted to Eka Kotebe General Hospital. The prevalence was higher than that of studies conducted in Nigeria (4.3%) [19] and Northern Ethiopia (0.8%) [14]. However, it was lower than a study finding from the Democratic Republic of Congo (32%) [20] and Indus Hospital Karachi, Pakistan (39%) [21]. The disparity could be attributable to differences in the study participants' characteristics and the sample size employed. For instance, the findings from Pakistan and the Congo were reported from a small number of participants among

critically ill patients, and the majority of the study participants in Northern Ethiopia were asymptomatic patients.

In a multivariable logistic regression analysis, age of patients, sex, co-morbidity among all admitted patients, diabetes mellitus, hypertension, and chronic kidney disease were found to be significant drivers of COVID-19 mortality.

Accordingly, people over the age of 50 had roughly eight times [AOR = 7.91, 95% CI: (2.34–25.69)] the odds of dying from COVID-19 compared to their younger counterparts. It's consistent with study findings throughout the world [22–26]. This might be explained by the fact that older adults had higher rates of COVID-19-related hospitalization, and the majority of those admitted had underlying medical disorders that were common among older adults.

On the other hand, males had a twofold higher risk of COVID-19 death than females. The greater death risks linked with COVID-19 for males could be due to associated comorbidities such as cardiovascular illnesses, hypertension, obesity, diabetes, or biological or genetic factors, but they could also be due to flaws in the health-care system [27–30].

The current finding also revealed that COVID-19 patients with diabetes mellitus had a 2.6-times greater risk of death. This could be due to the fact that diabetes might predispose patients to adverse outcomes and is a substantial risk factor for the severity and death of COVID-19 patients. This is supported by a number of research findings [23, 31–34], which might be due to a weakened innate immune system caused by chronic hyperglycemia, an over-active cytokine response, and hypercoagulability-related clinical impairments [35].

Another conclusion from multivariate logistic regression analysis was that COVID-19 patients with hypertension were nearly three times more likely to die, implying that hypertension is a major predictor of hospital mortality. This conclusion is backed up by a number of studies [31, 36, 37]. It could be owing to the fact that older people have a higher risk of cardiovascular disease and diabetes (all well-known risk factors for mortality in critical patients) than younger people do.

Chronic kidney diseases were a strong predictor of COVID-19 mortality. A COVID-19 patient with CKD had twelve times higher odds of death. In a similar study of the European population, patients with high creatinine levels and a history of previous CKD were found to have a higher rate of in-hospital death [30, 31, 38]. This may be linked to their weakened immune systems. In addition, non-survivors of COVID-19 showed higher levels of variables linked to renal illness, such as creatinine, blood urea, neutrophil count, and D-dimer [39].

## Limitation

Hence, many patients with one or more comorbidities were represented, and different clinical treatment regimens were implemented. This might lead to differing survival outcomes. Due to the cross-sectional nature of the study that was performed, the association between various factors and COVID-19-associated mortality may not indicate a cause-and-effect relationship. Moreover, this study included only in-hospital patients who tested positive. Some people may have developed symptoms in the community but were not tested, or they may have been asymptomatic.

## Conclusion and recommendations

The results of the current study showed that the magnitude of COVID-19 mortality among hospitalized COVID-19 patients was high. Moreover, age, gender, and presence of co-morbidity among all admitted patients—including diabetes, hypertension, and chronic kidney disease were—discovered to be determinants of COVID-19 mortality. Therefore, older COVID-19

patients and those with established comorbidities such as hypertension, diabetes, and end-stage renal disease should receive comprehensive preventative efforts, including vaccination.

## Supporting information

**S1 Table. Binary logistic regression table.**  
(DOCX)

## Acknowledgments

We would like to acknowledge the study participants and data collectors for this study.

## Author Contributions

**Conceptualization:** Genanew Kassie Getahun, Amare Dinku.

**Data curation:** Tewodros Shitemaw, Zelalem Negash.

**Formal analysis:** Genanew Kassie Getahun, Amare Dinku, Dube Jara, Zelalem Negash.

**Investigation:** Amare Dinku, Dube Jara, Tewodros Shitemaw.

**Methodology:** Genanew Kassie Getahun, Amare Dinku, Dube Jara, Tewodros Shitemaw, Zelalem Negash.

**Software:** Dube Jara.

**Supervision:** Amare Dinku, Dube Jara, Zelalem Negash.

**Validation:** Amare Dinku, Tewodros Shitemaw.

**Writing – review & editing:** Genanew Kassie Getahun.

## References

1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis.* 2020;34. <https://doi.org/10.1016/j.tmaid.2020.101623> PMID: 32179124
2. World Health Organization. Sustaining lives and livelihoods: a decision framework for calibrating social and movement measures during the COVID-19 pandemic.
3. Anand V, Verma L, Aggarwal A, Nanjundappa P, Rai H. COVID-19 and psychological distress: Lessons for India. *Plos one.* 2021 Aug 4; 16(8):e0255683. <https://doi.org/10.1371/journal.pone.0255683> PMID: 34347847
4. Abrams EM, Greenhawt M, Shaker M, Pinto AD, Sinha I, Singer A. The COVID-19 pandemic: Adverse effects on the social determinants of health in children and families. *Annals of Allergy, Asthma & Immunology.* 2022 Jan 1; 128(1):19–25. <https://doi.org/10.1016/j.anai.2021.10.022> PMID: 34699969
5. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is there low morbidity and mortality of COVID-19 in Africa?. *The American journal of tropical medicine and hygiene.* 2020 Aug; 103(2):564. <https://doi.org/10.4269/ajtmh.20-0474> PMID: 32484156
6. Skrip L, Derra K, Kaboré M, Noori N, Gansané A, Valéa I, et al. Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis. *International Journal of Infectious Diseases.* 2020 Dec 1; 101:194–200. <https://doi.org/10.1016/j.ijid.2020.09.1432> PMID: 32987177
7. Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess deaths associated with COVID-19, by age and race and ethnicity—United States, January 26–October 3, 2020. *Morbidity and Mortality Weekly Report.* 2020 Oct 10; 69(42):1522.
8. Kadowa I. Using evidence and analysis for an adaptive health system response to COVID-19 in Uganda in 2020. EQUINET Case study paper Kampala: Ministry of Health Uganda. 2020 Nov.



9. Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the impact of COVID-19 and the potential impact of the public health response on disease burden in Uganda. *The American journal of tropical medicine and hygiene*. 2020 Sep; 103(3):1191. <https://doi.org/10.4269/ajtmh.20-0546> PMID: 32705975
10. Lanyero B, Edea ZA, Musa EO, Watere SH, Mandalia ML, Livinus MC, et al. Readiness and early response to COVID-19: achievements, challenges and lessons learnt in Ethiopia. *BMJ global health*. 2021 Jun 1; 6(6):e005581. <https://doi.org/10.1136/bmjgh-2021-005581> PMID: 34112648
11. Sultan M, Kene D, Waganew W, Worku A, Azazh A, Girma B, et al. Clinical characteristics of COVID-19 related deaths in Ethiopia. *Ethiopian journal of health sciences*. 2021 Mar 1; 31(2). <https://doi.org/10.4314/ejhs.v31i2.3> PMID: 34158772
12. Cho SI, Yoon S, Lee HJ. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. *Scientific reports*. 2021 Mar 18; 11(1):6375. <https://doi.org/10.1038/s41598-021-85813-2> PMID: 33737679
13. Prieto-Alhambra D, Ballo E, Coma E, et al. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain. *International Journal of Epidemiology*. 2020 Dec; 49(6):1930–9.
14. Abore KW, Berasa AB, Titole AM. Epidemiological and Clinical Profile of Deaths due to COVID-19 among Hospitalized Patients in Sidama Region, Ethiopia. *Global Journal of Epidemiology and Infectious Disease*. 2022 Aug 25:69–77.
15. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. *SN comprehensive clinical medicine*. 2020 Aug; 2:1069–76. <https://doi.org/10.1007/s42399-020-00363-4> PMID: 32838147
16. Ogunjimi M, Haiduc AA, Harky A. Congenital heart disease and incremental risks of COVID-19. *Journal of Cardiac Surgery*. 2021 Feb; 36(2):433–5. <https://doi.org/10.1111/jocs.15246> PMID: 33331065
17. Degefu MA, Argaw M, Feyisa GL, Degefa S. Effects of urbanization on the relationship between green-space patterns and evolution of regional heat island in cities of Ethiopia. *Chinese Journal of Population, Resources and Environment*. 2021 Dec 1; 19(4):330–43.
18. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. Second Ed. A Wiley Interscience Publisher; 2000.
19. Abayomi A, Odukoya O, Osibogun A, et al. Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2021; 102:226–32. <https://doi.org/10.1016/j.ijid.2020.10.024> PMID: 33075534
20. Ditekemena JD, Nkamba DM, Mutwadi A, Mavoko HM, Siewe Fodjo JN, Luhata C, et al. COVID-19 vaccine acceptance in the Democratic Republic of Congo: a cross-sectional survey. *Vaccines*. 2021 Feb 14; 9(2):153. <https://doi.org/10.3390/vaccines9020153> PMID: 33672938
21. Sarfaraz S, Shaikh Q, Saleem SG, Rahim A, Herekar FF, Junejo S, et al. Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. *PloS one*. 2021 May 27; 16(5):e0251754. <https://doi.org/10.1371/journal.pone.0251754> PMID: 34043674
22. Nlandu Y, Mafuta D, Sakaji J, et al. Predictors of mortality in COVID-19 patients at Kinshasa Medical Center and a survival analysis: a retrospective cohort study. *BMC infectious diseases*. 2021 Dec; 21(1):1–1.
23. Silverio A, Di Maio M, Citro R, Esposito L, Iuliano G, Bellino M, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. *BMC cardiovascular disorders*. 2021 Dec; 21(1):1–3.
24. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. 2020;369.
25. Wu Z, McGoogan JMJJ Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. 2020; 323(13):1239–42.
26. Lee JY, Kim HA, Huh K, Hyun M, Rhee JY, Jang S, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. *Journal of Korean medical science*. 2020 Jun 15; 35(23). <https://doi.org/10.3346/jkms.2020.35.e223> PMID: 32537957
27. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. *Intervirolgy*. 2021; 64(1):36–47.

28. Gomez JM, Du-Fay-de-Lavallaz JM, Fugar S, Sarau A, Simmons JA, Clark B, et al. Sex differences in COVID-19 hospitalization and mortality. *Journal of Women's Health*. 2021 May 1; 30(5):646–53. <https://doi.org/10.1089/jwh.2020.8948> PMID: 33826864
29. Wei X, Xiao YT, Wang J, Chen R, Zhang W, Yang Y, et al. Sex differences in severity and mortality among patients with COVID-19: evidence from pooled literature analysis and insights from integrated bioinformatic analysis. *arXiv preprint arXiv:2003.13547*. 2020 Mar 30.
30. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. *PloS one*. 2020 Aug 26; 15(8):e0238215. <https://doi.org/10.1371/journal.pone.0238215> PMID: 32845926
31. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The association between presence of comorbidities and COVID-19 severity: a systematic review and meta-analysis. *Cerebrovascular Diseases*. 2021; 50(2):132–40. <https://doi.org/10.1159/000513288> PMID: 33530081
32. Collard D, Nurmohamed NS, Kaiser Y, Reeskamp LF, Dormans T, Moeniralam H, et al. Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. *BMJ open*. 2021 Feb 1; 11(2):e045482. <https://doi.org/10.1136/bmjopen-2020-045482> PMID: 33619201
33. Woolcott OO, Castilla-Bancayán JP. The effect of age on the association between diabetes and mortality in adult patients with COVID-19 in Mexico. *Scientific Reports*. 2021 Apr 16; 11(1):1–0.
34. Leulseged TW, Hassen IS, Maru EH, Zewde WC, Chamiso NW, Bayisa AB, et al. Characteristics and outcome profile of hospitalized African patients with COVID-19: The Ethiopian context. *PloS one*. 2021 Nov 9; 16(11):e0259454. <https://doi.org/10.1371/journal.pone.0259454> PMID: 34752481
35. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020 Apr 30; 382(18):1708–20. <https://doi.org/10.1056/NEJMoa2002032> PMID: 32109013
36. Dalan R, Ang LW, Tan WY, Fong SW, Tay WC, Chan YH, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020 Aug 7.
37. Parveen R, Sehar N, Bajpai R, Agarwal NB. Association of diabetes and hypertension with disease severity in covid-19 patients: a systematic literature review and exploratory meta-analysis. *Diabetes research and clinical practice*. 2020 Aug 1; 166:108295. <https://doi.org/10.1016/j.diabres.2020.108295> PMID: 32623032
38. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. *Intervirolgy*. 2021; 64(1):36–47.
39. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of COVID-19 patients.